問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Psychiatry

Division of General Internal Medicine

Division of Ophthalmology

更新時間：2023-09-19

藍先元Lane, Hsien-Yuan
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

  • tr14cmd@gmail.com

Recruiting Trial

5Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

藍先元

List

13Cases

2005-01-01 - 2008-11-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2020-12-01 - 2025-08-31

Phase II/III

Completed
A Phase 2B Randomized, Double-Blind, Placebo-and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia

  • Condition/Disease

    Schizophrenia

  • Test Drug

    MK-8189

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting4Sites

2023-01-01 - 2025-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-04-01 - 2026-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2011-11-01 - 2013-12-31

Phase II

A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response

  • Condition/Disease

    Major depressive disorder

  • Test Drug

    RO4917523

Participate Sites
3Sites

Terminated3Sites

2017-07-01 - 2018-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-12-01 - 2013-12-31

Phase III

A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia

  • Condition/Disease

    Schizophenia

  • Test Drug

    INVEGA SUSTENNA

Participate Sites
3Sites

Terminated3Sites

2020-01-24 - 2021-12-31

Phase II

A Phase 2a Proof-of-Concept Study of R-107 for the Treatment of Refractory Major Depressive Disorder

  • Condition/Disease

    Refractory Major Depressive Disorder

  • Test Drug

    R-107

Participate Sites
3Sites

Recruiting3Sites

2023-01-01 - 2025-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2012-01-05 - 2013-06-30

Phase III

A phase 3, multicenter, randomized, double-blind, placebo-controlled Trial of Fixed-dose OPC-34712 (4,2, and 1 mg/day) in the Treatment of Adults With Acute Schizophrenia

  • Condition/Disease

    Schizophrenia

  • Test Drug

    OPC-34712

Participate Sites
4Sites

Terminated4Sites

藍先元
China Medical University Hospital

Division of Psychiatry

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB